🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Urothelial Neoplasm

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors NCT05733000Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride The Evaluation of Molecular Markers From PRedittivI DNA of Clinical Outcomes in Patients With UROthelial Tumor NCT06863844n/a1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA NCT07413523NA1 site📍 Rozzano Istituto Clinico Humanitas · Tests: SBRT Chemoablation for Low-Grade Bladder Cancer NCT07019220Phase 21 site📍 Vienna Ekaterina Laukhtina · Tests: Gemcitabine Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract NCT07789119n/a1 site📍 Houston M.D. Anderson Cancer Center · Tests: biospecimen Collection GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453Phase 1, Phase 213 sites📍 New York📍 New York📍 Huntersville GI Innovation, Inc. · Tests: GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors NCT07557225NA1 site📍 Beijing Peking University First Hospital · Tests: 18F-T2 PET/CT Sacituzumab Govitecan Plus EV in Metastatic UC NCT04724018Phase 1, Phase 21 site📍 Boston Dana-Farber Cancer Institute · Tests: Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma NCT06364956Phase 1, Phase 28 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Tislelizumab combined with two predefined dose groups of palbociclib, RP2D dose Of Tislelizumab combined with palbocicl… Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed? NCT07037589n/a1 site📍 Uddevalla Vastra Gotaland Region · Tests: investigation setting (cystoscopy + CTU + cytology), Cystoscopy - CTU - cytology (if needed) A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites📍 New York📍 Huntersville📍 San Antonio Arvinas Inc. · Tests: ARV-6723, Pembrolizumab, SOC Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer NCT06892860Phase 23 sites📍 Paris📍 Madrid📍 London Queen Mary University of London · Tests: Avelumab Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors NCT05969041Phase 16 sites📍 Darlinghurst📍 Randwick📍 Westmead Myeloid Therapeutics · Tests: MT-302 (A) A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413Phase 123 sites📍 Goodyear📍 Phoenix📍 Duarte IDEAYA Biosciences · Tests: IDE892, IDE397 Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer NCT05775471Phase 21 site📍 Los Angeles Jonsson Comprehensive Cancer Center · Tests: Biopsy, Biospecimen Collection, Enfortumab Vedotin, MR Urography, Nephroureterectomy A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma NCT07390617n/a7 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Non-therapeutic Nerve Conduction Studies, Non-therapeutic assessment of patient-reported neuropathy A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer NCT06774131Phase 379 sites📍 Homewood📍 Chandler📍 Queen Creek UroGen Pharma Ltd. · Tests: UGN-104 Study of DCC-2812 in Participants With Advanced Genitourinary Cancers NCT06966024Phase 18 sites📍 Boston📍 Ann Arbor📍 St Louis Deciphera Pharmaceuticals, LLC · Tests: DCC-2812 A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites📍 Clovis📍 Los Angeles📍 Newport Beach Bristol-Myers Squibb · Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig MICROBIOTA AND BLADDER CANCER NCT07080333NA8 sites📍 Cannes📍 Marseille📍 Menton Centre Hospitalier Universitaire de Nice · Tests: biopsy Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer NCT06356155Phase 22 sites📍 Ann Arbor📍 Philadelphia University of Michigan Rogel Cancer Center · Tests: Enfortumab vedotin, Pembrolizumab A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer NCT05754853Phase 31 site📍 Beijing Shanghai Miracogen Inc. · Tests: MRG002, Docetaxel Injection, Paclitaxel Injection, Gemcitabine Hydrochloride for Injection, Pemetrexed Disodium Injecti… Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial NCT07726602n/a1 site📍 Portland OHSU Knight Cancer Institute · Tests: Non-Interventional Study Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy NCT06170177n/a1 site📍 Milan IRCCS San Raffaele · Tests: Radical Cystectomy Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer NCT05833867Phase 11 site📍 Cleveland Shilpa Gupta, MD · Tests: Sacituzumab govitecan, Adaptive Radiotherapy Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers NCT05296564Phase 1, Phase 21 site📍 Jerusalem Hadassah Medical Organization · Tests: CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT, Aldesleukin Bladder Cancer Screening Trial NCT05646485NA1 site📍 Dallas University of Texas Southwestern Medical Center · Tests: Urinalysis DBC-664 in Adult Patients With Solid Tumors NCT07705035Phase 16 sites📍 Denver📍 Grand Rapids📍 East Brunswick Duboce Biopharmaceuticals, Inc. · Tests: DBC-664 Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs NCT06652022NA2 sites📍 Beijing📍 Beijing Peking University First Hospital · Tests: Systematic therapy combined with radiotherapy, Systematic drug treatment Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) NCT07241793Phase 26 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Sun Yat-sen University · Tests: Adebrelimab, Trastuzumab Rezetecan
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy